The ACT‐ONE trial, a multicentre, randomised, double‐blind, placebo‐controlled, dose‐finding study of the anabolic/catabolic transforming agent, MT‐102 in subjects with cachexia related to stage III and IV non‐small cell lung cancer and colorectal cancer: study design

    loading  Checking for direct PDF access through Ovid


Abstract unavailable for this article.

    loading  Loading Related Articles